A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.
Also Known As:
2',3' Dideoxyadenosine; 2',3'-Dideoxyadenosine; ddA (Antiviral); Adenosine, 2',3'-dideoxy-
Networked: 12 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Okada, Kiyoki: 1 article (08/2008)
2. Kitajima, Akiko: 1 article (08/2008)
3. Mochida, Jun'ichi: 1 article (08/2008)
4. Esumi, Mariko: 1 article (08/2008)

Related Diseases

1. Acquired Immunodeficiency Syndrome (AIDS)
04/01/1990 - "In this report, we have compared the uptake, metabolism, and relevant enzymology of a novel anti-acquired immunodeficiency syndrome drug, 2'-fluoro-2',3'-dideoxyarabinosyladenine (2'-F-dd-ara-A) with the corresponding properties of its parent compound 2',3'-dideoxyadenosine (2',3'-ddAdo) in three human T cell lines, MOLT-4, ATH8, and CEM. "
08/01/1992 - "A high-performance liquid chromatographic method with precolumn fluorescence derivatization using 2-(5-chlorocarbonyl-2-oxazolyl)-5,6-methylenedioxybenzofu ran is described for the quantification of 2',3'-dideoxyinosine, a therapeutic drug for acquired immunodeficiency syndrome, and 2',3'-dideoxyadenosine, an anti-human-immunodeficiency-viral agent, in rat plasma. "
09/15/1990 - "2',3'-Dideoxyadenosine (ddA) is a nucleoside analogue with anti-HIV activity and one of its metabolic products, 2',3'-dideoxyinosine (ddI), has shown promising results in clinical trials for the treatment of acquired immunodeficiency syndrome (AIDS). "
05/01/1990 - "This article describes the pharmacokinetics of 2',3'-dideoxyadenosine (ddA) and 2',3'-dideoxyinosine (ddI) as determined during phase I clinical trials in patients with acquired immunodeficiency syndrome and acquired immunodeficiency syndrome-related complex. "
04/01/1987 - "We report that 2',3'-dideoxyadenosine and 2',3'-dideoxycytidine inhibit retroviral DNA synthesis and mRNA expression in T cells exposed to the virus that causes acquired immunodeficiency syndrome, and afford such cells long-term protection in vitro under conditions of substantial viral excess. "
2. Infection
3. Simian Acquired Immunodeficiency Syndrome
4. Sarcoma 180
5. Neoplasms (Cancer)

Related Drugs and Biologics

1. bis(p-chlorophenyl)acetic acid (DDA)
2. Didanosine (Videx)
3. Zalcitabine (Hivid)
4. Zidovudine (Retrovir)
5. Messenger RNA (mRNA)
6. Forskolin
7. DNA (Deoxyribonucleic Acid)
8. Adenylate Cyclase (Adenylyl Cyclase)
9. Adenosine
10. beta-apocarotenoid-14',13'-dioxygenase (ADO)